This test is most useful if any of these apply to you.
If you and your partner each carry a disease-causing FANCF variant, each pregnancy has a one in four chance of a child with FANCF-related Fanconi anemia. The disease develops when both copies of this gene are affected. It can cause bone marrow failure, physical differences present at birth, and a much higher risk of certain cancers. Someone with one disease-causing copy and one working copy is a carrier and doesn't develop this form of Fanconi anemia.
For a healthy adult, this result matters mainly for family planning and relatives. FANCF testing has an established role in identifying carriers and diagnosing the disease when both gene copies are affected. An increased cancer risk from carrying one disease-causing FANCF copy has not been established.
A DNA crosslink joins the two strands of DNA together and can block copying when a cell divides. The Fanconi anemia pathway coordinates proteins that help repair this damage. FANCF provides instructions for one of those proteins.
Cell studies show that the FANCF protein helps assemble and stabilize a group of repair proteins called the core complex. This complex activates FANCI and FANCD2, which help organize repair at damaged DNA. Loss of FANCF disrupts that process and makes cells unusually sensitive to DNA crosslinks.
Damage to blood-forming stem cells contributes to marrow failure. Experiments in mice lacking the related repair protein FANCD2 and an enzyme that removes formaldehyde showed that formaldehyde produced inside the body can damage these cells and deplete them. This helps explain one source of injury when the pathway fails, but it isn't a direct study of people with FANCF variants.
The disease varies widely. Physical differences can include short stature, changes in the thumbs or forearm bones, patches of darker or lighter skin, kidney abnormalities, and a smaller head. Some people have few or none of these features. Marrow failure often develops during childhood, though it can appear later, and cancer can sometimes be the first recognized problem.
Studies across Fanconi anemia types find that marrow failure most often begins within the first decade of life. These estimates pool several genes and aren't a FANCF-specific forecast.
In a U.S. cohort of 203 people with several genetic forms, solid tumors were a more common first major complication than leukemia by older adulthood. These analyses counted the first event among severe marrow failure, leukemia, and solid tumors, so they don't describe total lifetime cancer risk.
Cancers of the mouth and throat and gynecological cancers are prominent risks across Fanconi anemia. Head and neck cancers often occur much earlier than in the general population, and treatment is difficult because affected tissues are unusually sensitive to chemotherapy and radiation.
The U.S. cohort estimated median survival at 37 years. Its participants had different genetic forms and treatment histories and were enrolled over many years. That historical estimate doesn't predict the lifespan of someone receiving a FANCF result today.
FANCF is an uncommon cause of Fanconi anemia. An Indian study enrolled 181 affected people and identified the genetic cause in 164. Two of those genetically diagnosed cases involved FANCF, about 1.2%. FANCA accounted for more than half of that genetically diagnosed group.
An older European study found more physical abnormalities in the rare D, E, and F groups than in some common groups. It also linked variants that completely disabled FANCA to earlier anemia and more leukemia. Those FANCA findings haven't established the same relationship for FANCF.
The U.S. cohort found milder physical features and better survival in the broader core-complex group, largely reflecting FANCA and FANCC. Pooling those genes doesn't establish that FANCF disease is mild. Published FANCF cases remain too few to give a reliable individual forecast.
A carrier result requires a variant classified as pathogenic or likely pathogenic. A report that mentions a FANCF variant isn't automatically a carrier diagnosis: many DNA changes are harmless, and others have uncertain effects.
A Spanish study of 1,021 people referred for hereditary cancer testing did not establish an association between FANCF carrier status and cancer. A later population study involving more than 170,000 people also found no convincing FANCF cancer-risk signal. The evidence supports reproductive counseling for carriers; it doesn't support extra cancer screening solely because of one disease-causing FANCF variant. Your personal and family cancer history still matter.
Your inherited FANCF genotype is lifelong, so a confirmed result doesn't need routine repeat testing. Its value comes from using it in reproductive decisions, family testing, and the evaluation of symptoms.
A healthy carrier doesn't need Fanconi anemia surveillance solely because of this result. If you have confirmed Fanconi anemia, monitoring focuses on your blood counts and cancer risk. Blood counts are commonly checked every three to four months, with marrow examinations and cancer surveillance arranged through a specialist team.
FANCF Genotype is best interpreted alongside these tests.
FANCF Genotype is included in these pre-built panels.
A comprehensive DNA test that screens 154 genes linked to hereditary cancer syndromes, from breast and colon cancer to rare tumor predispositions.